Keytruda-Yervoy Combo of No Benefit in Advanced NSCLC, Trial Data Show

Keytruda-Yervoy Combo of No Benefit in Advanced NSCLC, Trial Data Show

285645

Keytruda-Yervoy Combo of No Benefit in Advanced NSCLC, Trial Data Show

First-line treatment with a combination of Yervoy (ipilimumab) and Keytruda (pembrolizumab) failed to prolong survival and delay disease progression in patients with advanced non-small cell lung cancer (NSCLC) compared with Keytruda alone, according to data from a Phase 3 trial. The KEYNOTE-598 (NCT03302234) trial involved patients whose tumors produced high levels of PD-L1 and harbored no mutations in the EGFR or ALK genes. Data also showed higher toxicity and risk of serious side effects with the combination…

You must be logged in to read/download the full post.